Naratuximab (Anti-TSPAN26 / CD37)
Synonyms: Anti-TSPAN26/CD37 Reference Antibody (naratuximab)
Naratuximab (Anti-TSPAN26 / CD37) is a humanised monoclonal antibody targeting CD37 (TSPAN26). It can be used to synthesise an ADC compound, naratuximab emtansine which is used in treatment of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). MW : 150 KD.
1 Citation
17 Nobel Prize winners
have used Selleck products
Shimon Sakaguchi
Nature Communications 2025;16, Article number:1325
David Baker
Dev Cell 2023;58(20):2163-2180.e9.
Michael Houghton
Cell Chem Biol 2020;27(7):780-792.e5
David Julius
Cell 2017;185-198.e16
Charles M. Rice
Cell 2018;172(3):423-438.e25
Quality Control
Mechanism of Action
| Description |
Naratuximab (Anti-TSPAN26 / CD37) is a humanised monoclonal antibody targeting CD37 (TSPAN26). It can be used to synthesise an ADC compound, naratuximab emtansine which is used in treatment of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). MW : 150 KD.
|
References |
|---|
Product Details
| CAS No. | 1622327-39-2 |
|---|---|
| Molecular Weight | 150 |
| Isotype | Human IgG1 |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
Comparison of Clones for
*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)
Tech Support
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.